UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33221 HERON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 94-2875566 (State or other jurisdicti ...

Heron Update Q4 2022 Earnings Call Forward-Looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We caution investors that forward-looking statements are based on management's expectations and assumptions as of the date of this presentation, and involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those ex ...

Heron Therapeutics, Inc. (NASDAQ:HRTX) Q4 2022 Earnings Conference Call March 23, 2023 4:30 PM ET Company Participants David Szekeres – Executive Vice President, Chief Operating Officer Barry Quart – Chairman and Chief Executive Officer John Poyhonen – President and Chief Commercial Officer Conference Call Participants Josh Schimmer – Evercore Brandon Folkes – Cantor Fitzgerald Serge Belanger – Needham and Company Operator Good day, ladies and gentlemen. Thank you for standing by. Welcome to the Heron Thera ...

Heron Update 2023 COWEN Conference March 7, 2023 Forward-Looking Statements This presentation contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We caution investors that forward-looking statements are based on management's expectations and assumptions as of the date of this presentation, and involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly ...